How many genomics targets can a portfolio afford?
- 1 August 2005
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 10 (15), 1057-1063
- https://doi.org/10.1016/s1359-6446(05)03498-7
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Macro trends in pharmaceutical innovationNature Reviews Drug Discovery, 2005
- Finishing the euchromatic sequence of the human genomeNature, 2004
- R&D Costs and Returns by Therapeutic CategoryDrug Information Journal, 2004
- Knockouts model the 100 best-selling drugs—will they model the next 100?Nature Reviews Drug Discovery, 2003
- The druggable genomeNature Reviews Drug Discovery, 2002
- Returns on Research and Development for 1990s New Drug IntroductionsPharmacoEconomics, 2002
- Initial sequencing and analysis of the human genomeNature, 2001
- Brief History of Antipyretic TherapyClinical Infectious Diseases, 2000
- Drug-like properties and the causes of poor solubility and poor permeabilityJournal of Pharmacological and Toxicological Methods, 2000
- Genomic sciences and the medicine of tomorrowNature Biotechnology, 1996